80年代以来,随着免疫学的进展,国内外开始应用淋巴因子激活的杀伤细胞(LA-K),对肿瘤进行治疗和防止肿瘤扩散的研究,取得了令人鼓舞的效果。在此基础上,我们采用人小量外周血,分离单个核细胞,经CD~3McAb作用制备增强的LAK细胞,应用于晚期癌症治疗,经临床观察,近期效果满意。现报告如下:1 资料与方法 LAK细胞的制备:取患者外周血5～10ml,肝素抗凝,用淋巴细胞分层液分离单个核细胞,生理盐水洗三次,计数细胞数,按1×10~6/ml加于含10％AB型人血清的MEM培养液内,加入CD~3McAb100ng/ml,置5％ Since the 1980s, with the development of immunology, the use of lymphokine-activated killer cells (LA-K) at home and abroad to treat tumors and prevent tumor proliferation has achieved encouraging results. On this basis, we used a small amount of human peripheral blood to isolate mononuclear cells, and the enhanced LAK cells were prepared through the action of CD-3McAb. The results were clinically observed and the recent results were satisfactory. The report is as follows: 1 Materials and methods Preparation of LAK cells: Take peripheral blood of patients 5 ~ 10ml, anticoagulation of heparin, use monolayer of lymphocytes to separate mononuclear cells, saline wash three times, count the number of cells, according to 1 × 10 ~ Add 6/ml to MEM medium containing 10% AB human serum, add CD~3McAb 100ng/ml, set 5%